Role of progranulin as a biomarker for Alzheimers disease

Biomarkers in Medicine

Volumn 4, Issue 1, 2010, Pages 37-50

  Sleegers, Kristel ^a,b,c   Brouwers, Nathalie ^a,b,c   Van Broeckhoven, Christine ^a,b,c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; Biomarker; Loss of function mutation; Missense mutation; Plasma; Progranulin

Indexed keywords

PROGRANULIN;

ALZHEIMER DISEASE; DISEASE MARKER; FAMILY HISTORY; LOSS OF FUNCTION MUTATION; MILD COGNITIVE IMPAIRMENT; MISSENSE MUTATION; NERVE DEGENERATION; PROTEIN BLOOD LEVEL; REVIEW; SCREENING TEST;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FRONTOTEMPORAL LOBAR DEGENERATION; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, NEUROLOGICAL; MUTATION; NEURODEGENERATIVE DISEASES;

EID: 77951668417     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.82     Document Type: Review

References (81)

1. Blennow K, Zetterberg H: Cerebrospinal fuid biomarkers for Alzheimer's disease. J. Alzheimers Dis. 18(2), 413-417 (2009).
2. Hye A, Lynham S, Thambisetty M et al.: Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(Pt 11), 3042-3050 (2006).
3. Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG: Proteomics-derived cerebrospinal fuid markers of autopsy-confrmed Alzheimer's disease. Biomarkers 14(7), 493-501 (2009).
4. Cruts M, Gijselinck I, van der Zee J et al.: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442(7105), 920-924 (2006). (Pubitemid 44285947)
5. Baker M, Mackenzie IR, Pickering-Brown SM et al.: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442(7105), 916-919 (2006). (Pubitemid 44285946)
6. Brouwers N, Nuytemans K, van der Zee J et al.: Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch. Neurol. 64(10), 1436-1446 (2007).
7. Le Ber I, Camuzat A, Hannequin D et al.: Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 131(Pt 3), 732-746 (2008).
8. Kelley BJ, Haidar W, Boeve BF et al.: Prominent phenotypic variability associated with mutations in progranulin. Neurobiol. Aging 30(5), 739-751 (2009).
9. Rademakers R, Baker M, Gass J et al.: Phenotypic variability associated with progranulin haploinsuffciency in patients with the common 1477C-T (Arg493X) mutation: an international initiative. Lancet Neurol. 6(10), 857-868 (2007).
10. Bhandari V, Palfree RG, Bateman A: Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc. Natl Aad. Sci. USA 89(5), 1715-1719 (1992).
11. Plowman GD, Green JM, Neubauer MG et al.: The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth. J. Biol. Chem. 267(18), 13073-13078 (1992).
12. Anakwe OO, Gerton GL: Acrosome biogenesis begins during meiosis: evidence from the synthesis and distribution of an acrosomal glycoprotein, acrogranin, during guinea pig spermatogenesis. Biol. Reprod. 42(2), 317-328 (1990).
13. Zhou J, Gao G, Crabb JW, Serrero G: Purifcation of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line. J. Biol. Chem. 268(15), 10863-10869 (1993).
14. Xu SQ, Tang D, Chamberlain S et al.: The granulin/epithelin precursor abrogates the requirement for the insulin-like growth factor 1 receptor for growth in vitro. J. Biol. Chem. 273(32), 20078-20083 (1998).
15. Zhu J, Nathan C, Jin W et al.: Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111(6), 867-878 (2002).
16. Kessenbrock K, Frohlich L, Sixt M et al.: Proteinase 3 and neutrophil elastase enhance infammation in mice by inactivating antiinfammatory progranulin. J. Clin. Invest. 118(7), 2438-2447 (2008).
17. Hrabal R, Chen Z, James S, Bennett HP, Ni F: The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat. Struct. Biol. 3(9), 747-752 (1996).
18. Daniel R, He Z, Carmichael KP, Halper J, Bateman A: Cellular localization of gene expression for progranulin. J. Histochem. Cytochem. 48(7), 999-1009 (2000).
19. He Z, Ong CH, Halper J, Bateman A: Progranulin is a mediator of the wound response. Nat. Med. 9(2), 225-229 (2003).
20. He Z, Bateman A: Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J. Mol. Med. 81(10), 600-612 (2003).
21. Lu R, Serrero G: Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proc. Natl Aad. Sci. USA 97(8), 3993-3998 (2000).
22. Kato M, Hasunuma N, Nakayama R et al.: Progranulin, a secreted tumorigenesis and dementia-related factor, regulates mouse hair growth. J. Dermatol. Sci. 53(3), 234-236 (2009).
23. Kojima Y, Ono K, Inoue K et al.: Progranulin expression in advanced human atherosclerotic plaque. Atherosclerosis 206(1), 102-108 (2009).
24. Gijselinck I, Van Broeckhoven C, Cruts M: Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. Hum. Mutat. 29(12), 1373-1386 (2008).
25. Maquat LE: Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat. Rev. Mol. Cell Biol. 5(2), 89-99 (2004).
26. Gijselinck I, van der Zee J, Engelborghs S et al.: Progranulin locus deletion in frontotemporal dementia. Hum. Mutat. 29(1), 53-58 (2008).
27. Rovelet-Lecrux A, Deramecourt V, Legallic S et al.: Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiol. Dis. 31(1), 41-45 (2008).
28. Cruts M, Van Broeckhoven C: Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet. 24(4), 186-194 (2008).
29. Baker CA, Manuelidis L: Unique infammatory RNA profles of microglia in Creutzfeldt-Jakob disease. Proc. Natl Aad. Sci. USA 100(2), 675-679 (2003).
30. Malaspina A, Kaushik N, de Belleroche J: Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem. 77(1), 132-145 (2001).
31. Van Damme P, Van Hoecke A, Lambrechts D et al.: Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J. Cell Biol. 181(1), 37-41 (2008).
32. Mukherjee O, Pastor P, Cairns NJ et al.: HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann. Neurol. 60(3), 314-322 (2006).
33. Shankaran SS, Capell A, Hruscha AT et al.: FTLD-U linked missense mutations in the progranulin gene reduce progranulin production and secretion. J. Biol. Chem. 283, 1744-1753 (2008).
34. Mukherjee O, Wang J, Gitcho M et al.: Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum. Mutat. 29(4), 512-521 (2008).
35. van der Zee J, Le Ber I, Maurer-Stroh S et al.: Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum. Mutat. 28(4), 416-(2007).
36. Neary D, Snowden JS, Gustafson L et al.: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6), 1546-1554 (1998)
37. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J. Neurol. Neurosurg. Psychiatr. 57(4), 416-418 (1994).
38. Arai T, Hasegawa M, Akiyama H et al.: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351(3), 602-611 (2006).
39. Neumann M, Sampathu DM, Kwong LK et al.: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796), 130-133 (2006).
40. Hutton M, Lendon CL, Rizzu P et al.: Association of missense and 5́-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393(6686), 702-705 (1998).
41. Rademakers R, Cruts M, Van Broeckhoven C: The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum. Mutat. 24(4), 277-295 (2004).
42. Watts GD, Wymer J, Kovach MJ et al.: Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36(4), 377-381 (2004).
43. Skibinski G, Parkinson NJ, Brown JM et al.: Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37(8), 806-808 (2005).
44. Mackenzie IR, Baborie A, Pickering-Brown S et al.: Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classifcation and relation to clinical phenotype, Acta Neuropathol. 112(5), 539-549 (2006).
45. Sampathu DM, Neumann M, Kwong LK et al.: Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am. J. Pathol. 169(4), 1343-1352 (2006).
46. Boeve BF, Hutton M: Refning frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch. Neurol. 65(4), 460-464 (2008).
47. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G: Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71(16), 1235-1239 (2008).
48. Sleegers K, Brouwers N, Van Damme P et al.: A serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann. Neurol. 65(5), 603-609 (2009).
49. Finch N, Baker M, Crook R et al.: Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132(Pt 3), 583-591 (2009).
50. Carecchio M, Fenoglio C, De Riz M et al.: Progranulin plasma levels as potential biomarker for the identifcation of GRN deletion carriers. A case with atypical onset as clinical amnestic mild cognitive impairment converted to Alzheimer's disease. J. Neurol. Sci. 287(1-2), 291-293 (2009).
51. Coppola G, Karydas A, Rademakers R et al.: Gene expression study on peripheral blood identifes progranulin mutations. Ann. Neurol. 64(1), 92-96 (2008).
52. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 19(2), 109-116 (1998).
53. Graham A, Davies R, Xuereb J et al.: Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 128(Pt 3), 597-605 (2005).
54. Taylor KI, Probst A, Miserez AR, Monsch AU, Tolnay M: Clinical course of neuropathologically confrmed frontal-variant Alzheimer's disease. Nat. Clin. Pract. Neurol. 4(4), 226-232 (2008).
55. Liscic RM, Storandt M, Cairns NJ, Morris JC: Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch. Neurol. 64(4), 535-540 (2007).
56. Uryu K, Nakashima-Yasuda H, Forman MS et al.: Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 67(6), 555-564 (2008).
57. Amador-Ortiz C, Lin WL, Ahmed Z et al.: TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 61(5), 435-445 (2007).
58. Higashi S, Iseki E, Yamamoto R et al.: Concurrence of TDP-43, tau and a-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 1184, 284-294 (2007)
59. Rohn TT: Caspase-cleaved TAR DNA-binding protein-43 is a major pathological fnding in Alzheimer's disease. Brain Res. 1228, 189-198 (2008).
60. Arai T, Mackenzie IR, Hasegawa M et al.: Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 117(2), 125-136 (2009).
61. Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C: Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet. 21(12), 664-672 (2005).
62. van der Zee J, Sleegers K, Van Broeckhoven C: The Alzheimer's disease-frontotemporal lobar degeneration spectrum. Neurology 71(15), 1191-1197 (2008).
63. van der Zee J, Rademakers R, Engelborghs S et al.: A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain 129(Pt 4), 841-852 (2006).
64. Behrens MI, Mukherjee O, Tu PH et al.: Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. Alzheimer Dis. Assoc. Disord. 21(1), 1-7 (2007).
65. Benussi L, Binetti G, Sina E et al.: A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol. Aging 29(3), 427-435 (2008).
66. Brouwers N, Sleegers K, Engelborghs S et al.: Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71(9), 656-664 (2008).
67. Pereson S, Wils H, Kleinberger G et al.: Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J. Pathol. 219(2), 173-181 (2009).
68. Irwin D, Lippa CF, Rosso A: Progranulin (PGRN) expression in ALS: an immunohistochemical study. J. Neurol. Sci. 276(1-2), 9-13 (2009).
69. Bernardi L, Tomaino C, Anfossi M et al.: Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol. Aging 13(11), 1825-1833 (2009).
70. van Swieten JC, Heutink P: Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 7(10), 965-974 (2008).
71. Vineis P, Schulte P, McMichael AJ: Misconceptions about the use of genetic tests in populations. Lancet 357(9257), 709-712 (2001).
72. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88(9), 1337-1342 (1998).
73. Youn BS, Bang SI, Kloting N et al.: Serum progranulin concentrations may be associated with macrophage infltration into omental adipose tissue. Diabetes 58(3), 627-636 (2009).
74. Serrero G, Ioffe OB: Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium. Hum. Pathol. 34(11), 1148-1154 (2003).
75. Jones MB, Michener CM, Blanchette JO et al.: The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin. Cancer Res. 9(1), 44-51 (2003).
76. Lovat F, Bitto A, Xu SQ et al.: Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis 30(5), 861-868 (2009).
77. Pan CX, Kinch MS, Kiener PA et al.: PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin. Cancer Res. 10(4), 1333-1337 (2004).
78. Cheung ST, Wong SY, Leung KL et al.: Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin. Cancer Res. 10(22), 7629-7636 (2004).
79. Ho JC, Ip YC, Cheung ST et al.: Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 47(5), 1524-1532 (2008).
80. Luchsinger JA, Gustafson DR: Adiposity, Type 2 diabetes, and Alzheimer's disease. J. Alzheimers Dis. 16(4), 693-704 (2009).
81. Geser F, Martinez-Lage M, Kwong LK, Lee VM, Trojanowski JQ: Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J. Neurol. 256(8), 1205-1214 (2009).